The FDA reminded sponsors and researchers that many registered clinical studies still fail to post results to ClinicalTrials.gov on time. In a notice, the agency said it found delinquency in results reporting across more than 2,200 sponsors tied to over 3,000 clinical trials. The FDA’s “friendly reminder” indicates continued enforcement pressure aimed at improving transparency for trial outcomes, not just study registration. For biotech and CROs, noncompliance can affect operational credibility with investigators and may raise regulatory friction during later submissions. The move adds to a broader tightening of digital accountability in clinical development, where sponsors face increasingly concrete expectations for reporting timelines and public availability of results.